

Edward J Wild

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5708334/edward-j-wild-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117 papers	8,049 citations	41 h-index	89 g-index
140 ext. papers	9,790 ext. citations	8.3 avg, IF	5.9 L-index

#	Paper	IF	Citations
117	Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource.. <i>Journal of Huntingtons Disease</i> , 2022 , 11, 59-69	1.9	1
116	CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy-like Phenotype.. <i>Movement Disorders</i> , 2022 ,	7	0
115	241 Intrathecal antisense oligonucleotide delivery in HD: experience from RG6042 programme and best practice considerations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A83.1-A83	5.5	
114	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. <i>Journal of Neurochemistry</i> , 2021 , 158, 539-553	6	5
113	Huntington's disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	7
112	Neuropsychiatric comorbidities in Huntington's and Parkinson's Disease: A United States claims database analysis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 126-137	5.3	2
111	Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease. <i>Journal of Neuroscience</i> , 2021 , 41, 780-796	6.6	8
110	Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting. <i>Parkinsonism and Related Disorders</i> , 2021 , 83, 56-62	3.6	1
109	The use of wearable/portable digital sensors in Huntington's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2021 , 83, 93-104	3.6	8
108	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , 2021 , 11, 3481	4.9	3
107	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology</i> , 2020 , 19, 502-512 ^{24.1}		56
106	Huntington's Disease Clinical Trials Corner: April 2020. <i>Journal of Huntingtons Disease</i> , 2020 , 9, 185-197	1.9	24
105	Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 52-60.2		6
104	Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2020 , 16, 529-546	15	80
103	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. <i>PLoS ONE</i> , 2020 , 15, e0233820	3.7	3
102	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	24
101	Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. <i>Molecular Psychiatry</i> , 2020 , 25, 3399-3412	15.1	19

100	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
99	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
98	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
97	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
96	One decade ago, one decade ahead in huntington's disease. <i>Movement Disorders</i> , 2019 , 34, 1434-1439	7	6
95	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI. <i>European Journal of Neuroscience</i> , 2019 , 49, 1632-1639	3.5	1
94	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048	17.2	237
93	Targeting Huntingtin Expression in Patients with Huntington's Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 2307-2316	59.2	319
92	Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 302-311	2.2	9
91	Huntington's Disease Clinical Trials Corner: January 2019. <i>Journal of Huntingtons Disease</i> , 2019 , 8, 115-125	1.9	19
90	Huntington's Disease Clinical Trials Corner: June 2019. <i>Journal of Huntingtons Disease</i> , 2019 , 8, 363-371	1.9	18
89	Fluid and imaging biomarkers for Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , 2019 , 97, 67-80	4.8	16
88	Huntington's Disease Clinical Trials Corner: February 2018. <i>Journal of Huntingtons Disease</i> , 2018 , 7, 89-98	1.9	36
87	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018 , 90, e717-e723	6.5	42
86	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018 , 8, 4260	4.9	17
85	Huntington's Disease Clinical Trials Corner: August 2018. <i>Journal of Huntingtons Disease</i> , 2018 , 7, 279-286	1.9	17
84	Physician perception versus true efficacy of tetrabenazine for Huntington's disease. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1537-1538	2.5	
83	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	67

82	Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis. <i>Parkinsonism and Related Disorders</i> , 2018 , 55, 55-60	3.6	1
81	Biofluid Biomarkers in Huntington's Disease. <i>Methods in Molecular Biology</i> , 2018 , 1780, 329-396	1.4	13
80	Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 582-585	2.2	31
79	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology, The</i> , 2017 , 16, 701-711	24.1	161
78	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology, The</i> , 2017 , 16, 601-609	24.1	172
77	Ghost Pills: A Case Report. <i>Annals of Internal Medicine</i> , 2017 , 166, 609	8	1
76	Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice. <i>Scientific Reports</i> , 2017 , 7, 14114	4.9	27
75	Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease". <i>Journal of Clinical Movement Disorders</i> , 2017 , 4, 19	2.8	8
74	Therapies targeting DNA and RNA in Huntington's disease. <i>Lancet Neurology, The</i> , 2017 , 16, 837-847	24.1	175
73	Huntington's Disease and Other Chorea 2017 , 248-283		
72	Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. <i>Journal of Huntingtons Disease</i> , 2017 , 6, 349-361	1.9	31
71	Clinical Trials Corner: September 2017. <i>Journal of Huntingtons Disease</i> , 2017 , 6, 255-263	1.9	28
70	PO002 Bacterial meningitis with myelopathy and cranial neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A13.2-A13	5.5	
69	Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays. <i>PLoS ONE</i> , 2017 , 12, e0189891	3.7	9
68	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. <i>Journal of Neurochemistry</i> , 2016 , 139, 22-5	6	37
67	George Huntington: a legacy of inquiry, empathy and hope. <i>Brain</i> , 2016 , 139, 2326-33	11.2	20
66	Huntington's Disease: The Most Curable Incurable Brain Disorder?. <i>EBioMedicine</i> , 2016 , 8, 3-4	8.8	5
65	D1 HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A34.1-A34.1	5.5	1

64	D4 Prediction of huntington's disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A35.1-A35	5.5	
63	J9 Probing huntington's disease phenocopy syndromes with next-generation sequencing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A78.2-A78	5.5	
62	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. <i>PLoS ONE</i> , 2016 , 11, e0163479	3.7	35
61	K4 The cost and value of a huntington's disease multidisciplinary team meeting. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, A80.2-A80	5.5	
60	Psychogenic non-epileptic seizures in early Huntington's disease. <i>Practical Neurology</i> , 2016 , 16, 452-454	2.4	2
59	Cerebrospinal Fluid Biomarkers for Huntington's Disease. <i>Journal of Huntingtons Disease</i> , 2016 , 5, 1-13	1.9	39
58	Huntington disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15005	51.1	672
57	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1979-86	15.9	144
56	Neuropsychiatry and White Matter Microstructure in Huntington's Disease. <i>Journal of Huntingtons Disease</i> , 2015 , 4, 239-49	1.9	27
55	Huntington disease: natural history, biomarkers and prospects for therapeutics. <i>Nature Reviews Neurology</i> , 2014 , 10, 204-16	15	600
54	Targets for future clinical trials in Huntington's disease: what's in the pipeline?. <i>Movement Disorders</i> , 2014 , 29, 1434-45	7	104
53	C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. <i>Neurology</i> , 2014 , 82, 292-9	6.5	152
52	D01 Quantification Of Huntingtin Species In Huntington's Disease Patient Leukocytes Using Electrochemiluminescence Immunoassays. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, A31-A32	5.5	
51	QUANTIFYING MUTANT HUNTINGTIN IN HUNTINGTON'S DISEASE CSF. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, e4.132-e4	5.5	1
50	Premanifest and Early Huntington's Disease 2014 ,		4
49	Suicidal ideation in a European Huntington's disease population. <i>Journal of Affective Disorders</i> , 2013 , 151, 248-58	6.6	59
48	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. <i>Lancet Neurology</i> , 2013 , 12, 637-49	24.1	557
47	The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients. <i>PLoS ONE</i> , 2013 , 8, e68951	3.7	39

46	Corpus callosal atrophy in premanifest and early Huntington's disease. <i>Journal of Huntingtons Disease</i> , 2013 , 2, 517-26	1.9	21
45	JAK/STAT Signalling in Huntington's Disease Immune Cells. <i>PLOS Currents</i> , 2013 , 5,		13
44	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. <i>Lancet Neurology, The</i> , 2012 , 11, 42-53	24.1	392
43	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. <i>Neurology</i> , 2012 , 78, 690-5	6.5	231
42	HDBuzz: empowering patients through accessible education. <i>Trends in Molecular Medicine</i> , 2012 , 18, 1-3	11.5	3
41	Biomarkers for Huntington's disease: an update. <i>Expert Opinion on Medical Diagnostics</i> , 2012 , 6, 371-5		9
40	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. <i>European Journal of Human Genetics</i> , 2012 , 20, 20-6	5.3	16
39	F06 A critical evaluation of inflammatory markers in Huntington's disease plasma. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, A23.1-A23	5.5	
38	F05 Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, A22.3-A23	5.5	
37	Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3731-6	15.9	97
36	Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. <i>Human Molecular Genetics</i> , 2011 , 20, 1937-51	5.6	96
35	Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1409-12	5.5	65
34	Abnormal peripheral chemokine profile in Huntington's disease. <i>PLOS Currents</i> , 2011 , 3, RRN1231		73
33	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. <i>PLOS Currents</i> , 2011 , 3, RRN1247		18
32	Brain-derived neurotrophic factor in patients with Huntington's disease. <i>PLoS ONE</i> , 2011 , 6, e22966	3.7	95
31	The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 756-63	5.5	90
30	Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. <i>American Journal of Neuroradiology</i> , 2010 , 31, 1036-41	4.4	69
29	Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease. <i>American Journal of Neuroradiology</i> , 2010 , 31, 711-9	4.4	82

28	Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. <i>Movement Disorders</i> , 2010 , 25, 888-95	7	12
27	Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. <i>PLOS Currents</i> , 2010 , 2,		64
26	Nonlinear Elastic Spline Registration: Evaluation with Longitudinal Huntington's Disease Data. <i>Lecture Notes in Computer Science</i> , 2010 , 128-139	0.9	1
25	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. <i>Lancet Neurology</i> , 2009 , 8, 791-801	24.1	721
24	Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. <i>Movement Disorders</i> , 2009 , 24, 932-6	7	42
23	Serial volumetric MRI in Parkinsonian disorders. <i>Movement Disorders</i> , 2009 , 24 Suppl 2, S691-8	7	23
22	Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. <i>Journal of Neurology</i> , 2009 , 256, 203-12	5.5	48
21	Harnessing immune alterations in neurodegenerative diseases. <i>Neuron</i> , 2009 , 64, 21-4	13.9	34
20	Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. <i>Neurology</i> , 2009 , 73, 1280-5	6.5	71
19	Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. <i>NeuroImage</i> , 2009 , 47, 1659-65	7.9	38
18	Defective emotion recognition in early HD is neuropsychologically and anatomically generic. <i>Neuropsychologia</i> , 2008 , 46, 2152-60	3.2	84
17	Biomarkers for Huntington's disease. <i>Expert Opinion on Medical Diagnostics</i> , 2008 , 2, 47-62		6
16	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. <i>Journal of Experimental Medicine</i> , 2008 , 205, 1869-77	16.6	437
15	Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. <i>Brain</i> , 2008 , 131, 2851-9	11.2	101
14	Rapid eye movement sleep disturbances in Huntington disease. <i>Archives of Neurology</i> , 2008 , 65, 482-8		166
13	Huntington's disease phenocopies are clinically and genetically heterogeneous. <i>Movement Disorders</i> , 2008 , 23, 716-20	7	93
12	Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 14424-9	11.5	104
11	Vasculitic presentation of staphylococcal meningitis. <i>Archives of Neurology</i> , 2007 , 64, 1788-9		10

10	Huntington's disease phenocopy syndromes. <i>Current Opinion in Neurology</i> , 2007 , 20, 681-7	7.1	63
9	Plasma neurofilament heavy chain levels in Huntington's disease. <i>Neuroscience Letters</i> , 2007 , 417, 231-3	3.3	14
8	The differential diagnosis of chorea. <i>Practical Neurology</i> , 2007 , 7, 360-73	2.4	53
7	Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. <i>Journal of Proteome Research</i> , 2007 , 6, 2833-40	5.6	173
6	Predict-HD and the future of therapeutic trials. <i>Lancet Neurology</i> , 2006 , 5, 724-5	24.1	17
5	Deja vu in neurology. <i>Journal of Neurology</i> , 2005 , 252, 1-7	5.5	62
4	Thyrotoxic periodic paralysis in a Maori patient. <i>New Zealand Medical Journal</i> , 2004 , 117, U1204	0.8	2
3	The domino inequalities: facets for the symmetric traveling salesman polytope. <i>Mathematical Programming</i> , 2003 , 98, 223-251	2.1	6
2	Huntington's disease		0
1	Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington's disease: the prospective HD-CSF study		2